Skip to main content
. Author manuscript; available in PMC: 2011 Dec 16.
Published in final edited form as: Vaccine. 2010 Sep 15;29(2):357–362. doi: 10.1016/j.vaccine.2010.08.099

Figure 2. TNFα and IFNγ contribute to the reduced bacterial burden mediated by mAb specific for F1 or LcrV after pulmonary exposure to fully virulent pgm-positive Y. pestis.

Figure 2

Bacterial burden in lung (A) and liver (B) tissue were measured in cohorts of mice (n=10 per group) that received treatments in parallel with those analyzed for survival in Figure 1. The measurements were made one day after injection of mAb (i.e. on day 2 after infection with Y. pestis). In comparison with mice treated only with control (Ctrl) mAb, mice treated with control mAb and 200 ug F1-specific mAb or 7.5 ug LcrV-specific mAb showed significantly reduced pulmonary and hepatic burden (all p<0.05 by ANOVA). Administration of neutralizing mAb specific for TNFα and IFNγ (aCyt) increased pulmonary burden in mice treated with LcrV-specific mAb and increased hepatic burden in mice treated with F1-specific mAb (p<0.0001 and p<0.001, respectively by Mann-Whitney tests). ns; not significant (i.e. p>0.05).